US Stock Insider Trading | IONIS Pharmaceuticals disclosed 8 insider transactions on February 2

K-LinePoet · 2026-02-04T18:53:50+00:00

Ionis Pharmaceuticals disclosed eight internal transactions on February 2, 2026, including Board Member Monia Brett P selling 63,000 shares on January 30. Additionally, other executives also engaged in stock sell transactions, totaling over $9 million. The company focuses on the development of antisense drugs, dedicated to meeting the needs of the pharmaceutical market.

K-LinePoet

2026-02-04 18:53:50

Abstract generation in progress

On February 2, 2026, IONIS Pharmaceuticals (IONS) disclosed eight insider trading transactions. Director Monia Brett P sold 63,000 shares on January 30, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 2, 2026	Executive	Swayze Eric	January 30, 2026	Sell	6,179	82.93	512,400
February 2, 2026	Executive	HOUGEN ELIZABETH L	January 30, 2026	Sell	6,988	83.24	581,700
February 2, 2026	Executive	BENNETT C FRANK	January 30, 2026	Sell	5,885	82.95	488,100
February 2, 2026	Executive	Baroldi Joseph	January 30, 2026	Sell	5,296	82.96	439,400
February 2, 2026	Executive	O’NEIL PATRICK R.	January 30, 2026	Sell	6,179	83.53	516,200
February 2, 2026	Executive	Birchler Brian	January 30, 2026	Sell	6,179	83.03	513,000
February 2, 2026	Executive	Schneider Eugene	January 30, 2026	Sell	6,179	83.45	515,600
February 2, 2026	Director	Monia Brett P	January 30, 2026	Sell	63,000	82.72	5.209 million
January 23, 2026	Executive	Devers Shannon L.	January 22, 2026	Sell	3,977	81.34	323,500
January 20, 2026	Director	Monia Brett P	January 16, 2026	Sell	44,000	74.82	3.294 million

【Company Profile】

IONIS Pharmaceuticals is a leader in the invention and development of antisense drugs. Using its new drug development platform, the company has developed numerous top-tier medicines. Antisense technology opens a pathway between genetics and pharmaceuticals. With its highly efficient and prolific drug development platform, the company can expand its own and its partners’ drug portfolios with antisense drugs to meet a large demand for medications. The company’s strategy is to focus on what it does best—finding and developing unique antisense drugs to become key turning points in clinical value. The company invents and conducts early-stage research on new drugs, then licenses these drugs to partners. It maximizes drug value by handing over the drugs to leading pharmaceutical companies for late-stage development, such as Biogen Idec, Bausch + Lomb, GSK, Sanofi, and Eli Lilly.

The company’s flagship product, KYNAMRO, is progressing toward the market for patients with familial hypercholesterolemia.

The company was founded in 1989 in California, USA.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.